{"id":"eptacog-alfa-activated","rwe":[{"pmid":"40694642","year":"2006","title":"Coagulation Factor VIIa.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"39245591","year":"2024","title":"[Acquired haemophilia: Update in 2024].","finding":"","journal":"La Revue de medecine interne","studyType":"Clinical Study"},{"pmid":"31769912","year":"2019","title":"A novel protocol for accurate and reliable postoperative bolus administration of recombinant factor VIIa using an automated mini-pump system.","finding":"","journal":"Haemophilia : the official journal of the World Federation of Hemophilia","studyType":"Clinical Study"},{"pmid":"31249981","year":"2019","title":"Eptacog Alfa (Activated) Is Physically and Chemically Stable over 24 Hours when Administered as Bolus Injections in an Automated Infusion Pump.","finding":"","journal":"TH open : companion journal to thrombosis and haemostasis","studyType":"Clinical Study"},{"pmid":"31124272","year":"2019","title":"Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.","finding":"","journal":"Journal of thrombosis and haemostasis : JTH","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Factor VII deficiency","category":"indication"},{"label":"Glanzmann's thrombasthenia","category":"indication"},{"label":"Hereditary factor IX deficiency disease","category":"indication"},{"label":"Hereditary factor VIII deficiency disease","category":"indication"},{"label":"Novo Nordisk A/S","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Novo Nordisk","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=EPTACOG ALFA (ACTIVATED)","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:16:19.143649+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:16:24.727071+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:16:19.216483+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPTACOG ALFA (ACTIVATED)","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:16:25.175754+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Coagulation factor VII exogenous protein","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:16:26.637770+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108334/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:16:26.302546+00:00"}},"allNames":"eptacog alfa","offLabel":[],"synonyms":["eptacog alfa (activated)","eptacog alfa"],"timeline":[{"date":"1996-02-23","type":"positive","source":"DrugCentral","milestone":"EMA approval (Novo Nordisk A/S)"}],"approvals":[{"date":"1996-02-23","orphan":false,"company":"Novo Nordisk A/S","regulator":"EMA"}],"brandName":"Eptacog Alfa","ecosystem":[{"indication":"Factor VII deficiency","otherDrugs":[],"globalPrevalence":26400},{"indication":"Glanzmann's thrombasthenia","otherDrugs":[],"globalPrevalence":null},{"indication":"Hereditary factor IX deficiency disease","otherDrugs":[],"globalPrevalence":null},{"indication":"Hereditary factor VIII deficiency disease","otherDrugs":[{"name":"desmopressin","slug":"desmopressin","company":"Ferring Pharms Inc"},{"name":"emicizumab","slug":"emicizumab","company":"Genentech Inc"},{"name":"vasopressin","slug":"vasopressin","company":"Parke Davis"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Eptacog Alfa is a recombinant form of human coagulation factor VIIa, which plays a critical role in the intrinsic pathway of blood coagulation. It works by binding to tissue factor and activating factor IX and factor X, ultimately leading to the formation of a stable fibrin clot."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5159","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=EPTACOG%20ALFA%20%28ACTIVATED%29","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPTACOG ALFA (ACTIVATED)","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T11:00:01.914501","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:16:27.927557+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"eptacog alfa (activated)","indications":{"approved":[{"name":"Factor VII deficiency","source":"DrugCentral","snomedId":37193007,"regulator":"FDA","prevalenceClass":"1-9 / 1 000 000","globalPrevalence":26400,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet ([EXPERT])"},{"name":"Glanzmann's thrombasthenia","source":"DrugCentral","snomedId":32942005,"regulator":"FDA"},{"name":"Hereditary factor IX deficiency disease","source":"DrugCentral","snomedId":41788008,"regulator":"FDA"},{"name":"Hereditary factor VIII deficiency disease","source":"DrugCentral","snomedId":28293008,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06883240","phase":"","title":"An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-04-29","conditions":["Von Willebrand Disease, Type 3"],"enrollment":40,"completionDate":"2026-11-01"},{"nctId":"NCT04563520","phase":"PHASE3","title":"SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-03","conditions":["Hemophilia A"],"enrollment":5,"completionDate":"2027-03"},{"nctId":"NCT03496883","phase":"PHASE3","title":"Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Joseph Broderick, MD","startDate":"2021-12-03","conditions":["Intracerebral Hemorrhage"],"enrollment":860,"completionDate":"2028-01-01"},{"nctId":"NCT04647227","phase":"PHASE4","title":"SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors","status":"RECRUITING","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2021-06-28","conditions":["Hemophilia A With Inhibitor","Hemophilia B With Inhibitor"],"enrollment":55,"completionDate":"2027-03-31"},{"nctId":"NCT07290634","phase":"","title":"Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion","status":"RECRUITING","sponsor":"Zeliha Alicikus","startDate":"2026-01-30","conditions":["Thromboembolus","Massive Blood Transfusion; Thrombocytopenia","Trauma"],"enrollment":4,"completionDate":"2026-06-30"},{"nctId":"NCT04023019","phase":"","title":"Treatment of Hemophilia A Patients With FVIII Inhibitors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-03-17","conditions":["Hemophilia A"],"enrollment":120,"completionDate":"2029-06"},{"nctId":"NCT05281718","phase":"EARLY_PHASE1","title":"Factor IX as Adjunctive Therapy to Emicizumab (EMIX)","status":"COMPLETED","sponsor":"Tulane University","startDate":"2022-08-01","conditions":["Hemophilia A"],"enrollment":12,"completionDate":"2024-07-14"},{"nctId":"NCT04595617","phase":"NA","title":"Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2021-01-06","conditions":["Glanzmann Thrombasthenia"],"enrollment":28,"completionDate":"2023-07-06"},{"nctId":"NCT01830712","phase":"","title":"A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-04","conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors"],"enrollment":15,"completionDate":"2011-08"},{"nctId":"NCT01561391","phase":"PHASE4","title":"Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1998-04","conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors"],"enrollment":36,"completionDate":"2004-05"},{"nctId":"NCT04789954","phase":"EARLY_PHASE1","title":"Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors","status":"COMPLETED","sponsor":"AryoGen Pharmed Co.","startDate":"2020-12-29","conditions":["Hemophilia A With Inhibitor","Hemophilia B With Inhibitor"],"enrollment":14,"completionDate":"2022-07-31"},{"nctId":"NCT05487976","phase":"PHASE3","title":"Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-04-28","conditions":["Hemophilia A","Hemophilia B"],"enrollment":50,"completionDate":"2023-04"},{"nctId":"NCT04723979","phase":"","title":"NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2020-05-01","conditions":["Post Partum Hemorrhage"],"enrollment":3322,"completionDate":"2021-01-31"},{"nctId":"NCT04548791","phase":"PHASE1,PHASE2","title":"Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders","status":"TERMINATED","sponsor":"Catalyst Biosciences","startDate":"2021-05-17","conditions":["Factor VII Deficiency","Glanzmann Thrombasthenia","Hemophilia A With Inhibitor"],"enrollment":19,"completionDate":"2021-12-03"},{"nctId":"NCT04489537","phase":"PHASE3","title":"Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B","status":"TERMINATED","sponsor":"Catalyst Biosciences","startDate":"2021-05-04","conditions":["Hemophilia A With Inhibitor","Hemophilia B With Inhibitor"],"enrollment":18,"completionDate":"2021-12-01"},{"nctId":"NCT03407651","phase":"PHASE2","title":"Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B","status":"COMPLETED","sponsor":"Catalyst Biosciences","startDate":"2017-12-18","conditions":["Hemophilia A With Inhibitor","Hemophilia B With Inhibitor"],"enrollment":11,"completionDate":"2019-04-13"},{"nctId":"NCT04072237","phase":"PHASE1","title":"Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia","status":"COMPLETED","sponsor":"Catalyst Biosciences","startDate":"2019-09-24","conditions":["Hemophilia A","Hemophilia B","Hemophilia A With Inhibitor","Hemophilia B With Inhibitor","Hemophilia A Without Inhibitor","Hemophilia B Without Inhibitor"],"enrollment":11,"completionDate":"2020-06-17"},{"nctId":"NCT01757405","phase":"PHASE3","title":"Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2013-02-20","conditions":["Hemophilia A","Hemophilia B"],"enrollment":40,"completionDate":"2014-11-11"},{"nctId":"NCT03935334","phase":"PHASE3","title":"Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors","status":"COMPLETED","sponsor":"AryoGen Pharmed Co.","startDate":"2018-07-23","conditions":["Hemophilia A or B With Inhibitor"],"enrollment":48,"completionDate":"2021-02-03"},{"nctId":"NCT04444856","phase":"","title":"Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-06-29","conditions":["Severe Postpartum Haemorrhage"],"enrollment":225,"completionDate":"2021-01-13"},{"nctId":"NCT04424563","phase":"","title":"Activated Factor Seven in Traumatic Retro Peritoneal Hematoma","status":"COMPLETED","sponsor":"King Abdul Aziz Specialist Hospital","startDate":"2017-05-05","conditions":["Traumatic Bleeding"],"enrollment":80,"completionDate":"2019-12-30"},{"nctId":"NCT02484638","phase":"PHASE2,PHASE3","title":"Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors","status":"TERMINATED","sponsor":"CSL Behring","startDate":"2015-07-23","conditions":["Hemophilia A With Inhibitors","Hemophilia B With Inhibitors"],"enrollment":25,"completionDate":"2018-03-28"},{"nctId":"NCT03287999","phase":"","title":"Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B","status":"UNKNOWN","sponsor":"Royal Free Hospital NHS Foundation Trust","startDate":"2017-09-19","conditions":["Haemophilia"],"enrollment":250,"completionDate":"2020-10-02"},{"nctId":"NCT03251547","phase":"","title":"Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia","status":"COMPLETED","sponsor":"Universiti Sains Malaysia","startDate":"2017-08-21","conditions":["Massive Hemorrhage","Massive Blood Loss","Massive Blood Transfusion; Thrombocytopenia"],"enrollment":76,"completionDate":"2017-11-15"},{"nctId":"NCT00951405","phase":"PHASE2","title":"Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09-01","conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors"],"enrollment":23,"completionDate":"2011-03-29"},{"nctId":"NCT02900690","phase":"","title":"Health Economics Evaluation of the Management of Severe Postpartum Hemorrhage: Comparison of Recombinant Activated Factor VII Strategy to the Reference Strategy","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2010-04-22","conditions":["Health Care Cost","Post Partum Haemorrhage"],"enrollment":84,"completionDate":"2010-11-05"},{"nctId":"NCT00810888","phase":"PHASE2","title":"The Spot Sign for Predicting and Treating ICH Growth Study","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2010-11","conditions":["Intracerebral Hemorrhage"],"enrollment":92,"completionDate":"2016-04"},{"nctId":"NCT01876745","phase":"","title":"A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-10-07","conditions":["Congenital Bleeding Disorder","Glanzmann's Disease"],"enrollment":4,"completionDate":"2017-06-01"},{"nctId":"NCT01392547","phase":"PHASE3","title":"Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-07","conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors"],"enrollment":72,"completionDate":"2012-08"},{"nctId":"NCT02470871","phase":"PHASE1","title":"Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2015-07","conditions":["Congenital Coagulation Factor VII Deficiency"],"enrollment":9,"completionDate":"2016-10"},{"nctId":"NCT00486278","phase":"PHASE2","title":"Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-06","conditions":["Congenital Bleeding Disorder","Haemophilia A","Haemophilia B"],"enrollment":51,"completionDate":"2010-06"},{"nctId":"NCT01586936","phase":"","title":"Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1999-03-10","conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors"],"enrollment":9,"completionDate":"2010-03-09"},{"nctId":"NCT01564563","phase":"PHASE2","title":"Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2002-06-28","conditions":["Acquired Bleeding Disorder","Bleeding During/Following Surgery"],"enrollment":11,"completionDate":"2003-10-27"},{"nctId":"NCT00124293","phase":"","title":"Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-10-06","conditions":["Acquired Bleeding Disorder","Trauma"],"enrollment":63,"completionDate":"2005-11-23"},{"nctId":"NCT01579955","phase":"","title":"Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1999-03-10","conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors"],"enrollment":321,"completionDate":"2010-03-09"},{"nctId":"NCT01579968","phase":"","title":"Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1999-03-10","conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors"],"enrollment":86,"completionDate":"2010-03-09"},{"nctId":"NCT01561417","phase":"PHASE1","title":"Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-04","conditions":["Acquired Bleeding Disorder","Acquired Haemophilia","Congenital Bleeding Disorder","Congenital FVII Deficiency","Glanzmann's Disease","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors","Healthy"],"enrollment":28,"completionDate":"2006-09"},{"nctId":"NCT00426803","phase":"PHASE2","title":"Recombinant Factor VIIa in Acute Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08","conditions":["Acquired Bleeding Disorder","Intracerebral Haemorrhage"],"enrollment":400,"completionDate":"2004-06"},{"nctId":"NCT01563458","phase":"PHASE2","title":"Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-08","conditions":["Acquired Bleeding Disorder","Bleeding During/Following Surgery"],"enrollment":208,"completionDate":"2003-08"},{"nctId":"NCT00102037","phase":"PHASE2","title":"Use of Activated Recombinant FVII in Spinal Surgery","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-07","conditions":["Acquired Bleeding Disorder","Spinal Fusion"],"enrollment":50,"completionDate":"2006-02"},{"nctId":"NCT01562821","phase":"PHASE2","title":"Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-07","conditions":["Acquired Bleeding Disorder","Cirrhosis"],"enrollment":235,"completionDate":"2002-12"},{"nctId":"NCT01563445","phase":"PHASE2","title":"Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-11","conditions":["Acquired Bleeding Disorder","Intracerebral Haemorrhage"],"enrollment":40,"completionDate":"2003-03"},{"nctId":"NCT01563471","phase":"PHASE1","title":"Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-10","conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors","Healthy"],"enrollment":39,"completionDate":"2002-07"},{"nctId":"NCT01563523","phase":"PHASE2","title":"Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-03","conditions":["Acquired Bleeding Disorder","Trauma"],"enrollment":283,"completionDate":"2003-10"},{"nctId":"NCT00154492","phase":"PHASE2","title":"Use of NovoSeven® in Active Variceal Bleeding","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-04","conditions":["Acquired Bleeding Disorder","Cirrhosis"],"enrollment":265,"completionDate":"2006-08"},{"nctId":"NCT01601457","phase":"PHASE2","title":"Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-09","conditions":["Acquired Bleeding Disorder","Trauma"],"enrollment":48,"completionDate":"2004-04"},{"nctId":"NCT01566786","phase":"PHASE2","title":"Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-08","conditions":["Acquired Bleeding Disorder","Intracerebral Haemorrhage"],"enrollment":48,"completionDate":"2002-10"},{"nctId":"NCT01562574","phase":"PHASE3","title":"Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-01","conditions":["Acquired Bleeding Disorder","Cardiac Surgery Requiring Cardiopulmonary Bypass"],"enrollment":82,"completionDate":"2004-08"},{"nctId":"NCT00123591","phase":"PHASE2","title":"Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-01","conditions":["Acquired Bleeding Disorder","Trauma"],"enrollment":96,"completionDate":"2006-05"},{"nctId":"NCT01779921","phase":"","title":"Treatment of Congenital Factor VII Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-10","conditions":["Congenital Bleeding Disorder","Congenital FVII Deficiency"],"enrollment":163,"completionDate":"2012-01"},{"nctId":"NCT00571584","phase":"PHASE4","title":"High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-11","conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors"],"enrollment":24,"completionDate":"2004-03"},{"nctId":"NCT00127283","phase":"PHASE3","title":"Recombinant Factor VIIa in Acute Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-05","conditions":["Acquired Bleeding Disorder","Intracerebral Haemorrhage"],"enrollment":829,"completionDate":"2007-01"},{"nctId":"NCT00104455","phase":"PHASE1","title":"Dose Response to Recombinant Factor VIIa When Administered for Bleed","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-06","conditions":["Congenital Bleeding Disorder","Healthy"],"enrollment":64,"completionDate":"2004-11"},{"nctId":"NCT00108797","phase":"PHASE4","title":"Trial of NovoSeven® in Haemophilia - Joint Bleeds","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-09","conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors"],"enrollment":42,"completionDate":"2006-02"},{"nctId":"NCT00108758","phase":"PHASE2","title":"Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-03","conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors"],"enrollment":23,"completionDate":"2005-11"},{"nctId":"NCT01561352","phase":"PHASE2","title":"Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-09","conditions":["Other Haemostasis Disorder","Haemorrhagic Cystitis"],"enrollment":7,"completionDate":"2003-11"},{"nctId":"NCT01562587","phase":"PHASE1","title":"Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-09","conditions":["Congenital Bleeding Disorder","Haemophilia A","Haemophilia B"],"enrollment":18,"completionDate":"2003-05"},{"nctId":"NCT00154427","phase":"PHASE2","title":"Use of Activated Recombinant Human Factor VII in Cardiac Surgery","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2004-08","conditions":["Acquired Bleeding Disorder","Cardiac Surgery Requiring Cardiopulmonary Bypass"],"enrollment":172,"completionDate":"2007-11"},{"nctId":"NCT00703911","phase":"","title":"Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-03","conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors"],"enrollment":102,"completionDate":"2010-07"},{"nctId":"NCT01601613","phase":"PHASE2","title":"Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-07","conditions":["Acquired Bleeding Disorder","Dengue Haemorrhagic Fever"],"enrollment":28,"completionDate":"2002-11"},{"nctId":"NCT01562158","phase":"PHASE2","title":"Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-04","conditions":["Acquired Bleeding Disorder","Bleeding During/Following Surgery"],"enrollment":100,"completionDate":"2003-10"},{"nctId":"NCT00882778","phase":"","title":"PROPACT: Retrospective Prophylaxis Patient Case Collection","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-04","conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors"],"enrollment":86,"completionDate":"2010-05"},{"nctId":"NCT00697320","phase":"","title":"Observational Study on the Efficacy and Safety of NovoSeven® During \"Real-life\" Usage in Germany","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06","conditions":["Congenital Bleeding Disorder","Congenital FVII Deficiency","Glanzmann's Disease","Acquired Bleeding Disorder","Acquired Haemophilia"],"enrollment":64,"completionDate":"2010-12"},{"nctId":"NCT01561937","phase":"PHASE1","title":"Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-01","conditions":["Haemostasis","Healthy"],"enrollment":127,"completionDate":"2008-07"},{"nctId":"NCT01561950","phase":"PHASE1","title":"Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2008-05","conditions":["Haemostasis","Healthy"],"enrollment":91,"completionDate":"2009-01"},{"nctId":"NCT01561924","phase":"PHASE1","title":"Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-11","conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors"],"enrollment":17,"completionDate":"2006-05"},{"nctId":"NCT00266006","phase":"PHASE2","title":"Factor VIIa in Acute Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-01","conditions":["Acquired Bleeding Disorder","Intracerebral Haemorrhage"],"enrollment":90,"completionDate":"2007-04"},{"nctId":"NCT00710619","phase":"","title":"Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06","conditions":["Congenital Bleeding Disorder","Haemophilia A With Inhibitors","Haemophilia B With Inhibitors"],"enrollment":52,"completionDate":"2009-07"},{"nctId":"NCT00853086","phase":"","title":"Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":["Congenital Bleeding Disorder","Haemophilia A","Haemophilia B"],"enrollment":139,"completionDate":"2011-06"},{"nctId":"NCT00951873","phase":"PHASE1","title":"A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-07","conditions":["Congenital Bleeding Disorder","Haemophilia A","Haemophilia B","Healthy"],"enrollment":38,"completionDate":"2010-04"},{"nctId":"NCT00922792","phase":"PHASE1","title":"Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-06","conditions":["Congenital Bleeding Disorder","Haemophilia A","Haemophilia B"],"enrollment":8,"completionDate":"2009-09"},{"nctId":"NCT01562457","phase":"PHASE1","title":"Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-11","conditions":["Congenital Bleeding Disorder","Haemophilia A","Haemophilia B"],"enrollment":30,"completionDate":"2006-04"},{"nctId":"NCT01625390","phase":"PHASE2,PHASE3","title":"A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-06","conditions":["Hemophilia A, Hemophilia B"],"enrollment":10,"completionDate":"2014-03"},{"nctId":"NCT01220141","phase":"","title":"Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-11","conditions":["Congenital Bleeding Disorder","Haemophilia A","Haemophilia B"],"enrollment":51,"completionDate":"2015-03"},{"nctId":"NCT00370877","phase":"PHASE4","title":"rhuFVIIa in Post-partum Hemorrhage","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2007-04","conditions":["Postpartum Hemorrhage"],"enrollment":84,"completionDate":"2010-11"},{"nctId":"NCT01476423","phase":"","title":"Observational Registry of the Treatment of Glanzmann's Thrombasthenia","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-01","conditions":["Congenital Bleeding Disorder","Glanzmann's Disease"],"enrollment":218,"completionDate":"2011-10"},{"nctId":"NCT01949792","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09","conditions":["Congenital Bleeding Disorder","Haemophilia A","Haemophilia A With Inhibitors","Haemophilia B","Haemophilia B With Inhibitors"],"enrollment":6,"completionDate":"2013-11"},{"nctId":"NCT01234545","phase":"","title":"Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-10","conditions":["Congenital Bleeding Disorder","Haemophilia A","Haemophilia B"],"enrollment":35,"completionDate":"2012-04"},{"nctId":"NCT01312636","phase":"","title":"Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-03","conditions":["Congenital Bleeding Disorder","Congenital FVII Deficiency"],"enrollment":36,"completionDate":"2014-09"},{"nctId":"NCT00184548","phase":"PHASE3","title":"Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2005-10","conditions":["Acquired Bleeding Disorder","Trauma"],"enrollment":554,"completionDate":"2008-09"},{"nctId":"NCT02084810","phase":"PHASE1","title":"Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2014-03","conditions":["Congenital Bleeding Disorder","Haemophilia A","Haemophilia A With Inhibitors","Haemophilia B","Haemophilia B With Inhibitors","Healthy"],"enrollment":0,"completionDate":"2014-07"},{"nctId":"NCT01285089","phase":"","title":"Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-12","conditions":["Acquired Bleeding Disorder","Acquired Haemophilia"],"enrollment":21,"completionDate":"2013-10"},{"nctId":"NCT01352143","phase":"","title":"Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Emory University","startDate":"2011-03","conditions":["Cardiopulmonary Bypass"],"enrollment":24,"completionDate":"2012-06"},{"nctId":"NCT01105546","phase":"PHASE2","title":"rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2010-12","conditions":["Hemophilia A With Inhibitors"],"enrollment":50,"completionDate":"2014-04"},{"nctId":"NCT01269138","phase":"","title":"Treatment of Inherited Factor VII Deficiency","status":"COMPLETED","sponsor":"University of L'Aquila","startDate":"2007-01","conditions":["Factor VII Deficiency"],"enrollment":223,"completionDate":"2012-11"},{"nctId":"NCT00284193","phase":"PHASE4","title":"Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2005-01","conditions":["Hemophilia A"],"enrollment":5,"completionDate":"2009-11"},{"nctId":"NCT00323570","phase":"PHASE3","title":"Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":["Acquired Bleeding Disorder","Trauma"],"enrollment":0,"completionDate":"2007-06"},{"nctId":"NCT00770718","phase":"PHASE1","title":"Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage","status":"TERMINATED","sponsor":"University of Utah","startDate":"2008-04","conditions":["Intracranial Hemorrhage"],"enrollment":2,"completionDate":"2010-04"},{"nctId":"NCT00375323","phase":"PHASE3","title":"Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"","conditions":["Hemophilia A"],"enrollment":0,"completionDate":""},{"nctId":"NCT00222625","phase":"PHASE2","title":"rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets","status":"UNKNOWN","sponsor":"University Of Perugia","startDate":"2005-09","conditions":["Intracerebral Hemorrhage"],"enrollment":32,"completionDate":"2006-09"},{"nctId":"NCT00214656","phase":"PHASE3","title":"\"Salvage Use\" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery","status":"UNKNOWN","sponsor":"Austin Health","startDate":"2005-06","conditions":["Myocardial Ischemia","Blood Coagulation Disorders","Coronary Artery Disease","Heart Valve Diseases"],"enrollment":40,"completionDate":"2008-06"}],"_emaApprovals":[{"date":"1996-02-23","status":"Authorised","company":"Novo Nordisk A/S"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"006099","VANDF":"4021161","RXNORM":"253149","UMLSCUI":"C0795575","chemblId":"CHEMBL2108334","ChEMBL_ID":"CHEMBL2108405","DRUGBANK_ID":"DB00036","SNOMEDCT_US":"116066006","MESH_SUPPLEMENTAL_RECORD_UI":"C103587"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Novo Nordisk","relationship":"Original Developer"}],"publicationCount":13,"therapeuticAreas":["Rare Disease"],"biosimilarFilings":[],"originalDeveloper":"Novo Nordisk A/S","recentPublications":[{"date":"2006","pmid":"40694642","title":"Coagulation Factor VIIa.","journal":""},{"date":"2024 Nov","pmid":"39245591","title":"[Acquired haemophilia: Update in 2024].","journal":"La Revue de medecine interne"},{"date":"2019 Nov","pmid":"31769912","title":"A novel protocol for accurate and reliable postoperative bolus administration of recombinant factor VIIa using an automated mini-pump system.","journal":"Haemophilia : the official journal of the World Federation of Hemophilia"},{"date":"2019 Jan","pmid":"31249981","title":"Eptacog Alfa (Activated) Is Physically and Chemically Stable over 24 Hours when Administered as Bolus Injections in an Automated Infusion Pump.","journal":"TH open : companion journal to thrombosis and haemostasis"},{"date":"2019 Sep","pmid":"31124272","title":"Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.","journal":"Journal of thrombosis and haemostasis : JTH"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Novo Nordisk","companyId":"novo-nordisk","modality":"Recombinant protein","firstApprovalDate":"1996","aiSummary":"Eptacog Alfa is a recombinant human protein that belongs to the class of exogenous proteins and targets coagulation factor VII. It is used to treat various bleeding disorders, including acquired and congenital bleeding disorders, as well as post-partum hemorrhage and traumatic bleeding.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"1996-02-23T00:00:00.000Z","mah":"Novo Nordisk A/S","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2022-05-19T00:00:00.000Z","mah":"UGA Biopharma","brand_name_local":"HemAryo","application_number":"EMEA/H/C/005547"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:16:27.927557+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}